Skip to content

Clinical study of low frequency electrotherapy of midnight-noon meridional flow combined with repetitive transcranial magnetic stimulation in the treatment of insomnia after ischemic stroke

Clinical study of low frequency electrotherapy of midnight-noon meridional flow combined with repetitive transcranial magnetic stimulation in the treatment of insomnia after ischemic stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074051
Enrollment
Unknown
Registered
2023-07-28
Start date
2023-07-31
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Midafternoon stream low frequency electrotherapy group :Meridian stream low-frequency electrotherapy group: Patients received meridian stream low-frequency electrotherapy (instrument used by Beijing J
Treatment points: the point opened at that time (2-4) + Baihui, Shenmen, four Shencong, Neiguan, three Yin Jiao, Yintang, sleeping, God ting, wind pool, sun, foot three Li, Shanzhong (through dialecti
Treatment frequency: 9 (composite waveform)
Treatment intensity: 0-99mA (mainly tolerated by patients), routine 30 mA, 30 min each treatment, once a day,5d/w, a total of 4 weeks
The transcranial magnetic stimulation group was repeated:Patients receiving rTMS treatment rTMS treatment protocol: Treatment position: lying position
Treatment frequency: 1HZ
Treatment targets: right dorsolateral frontal region
Treatment intensity: 80%-120% threshold, stimulation 8S, intermittent 3S, once a day, 5 times a week, 15 minutes each time
Treatment group of midafternoon flow low frequency electric combined with repetitive transcranial magnetic stimulation:Meridian flow low frequency electrotherapy combined with repetitive transcranial
Drug treatment group:Routine oral medication (dexzopiclone) was given before going to bed according to the doctor's advice. Treatment plan: Dexzopiclone was taken orally 2mg/ time, once/day, before g

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1)Patients who meet the diagnostic criteria of ischemic stroke in the "Diagnostic Points of Various Cerebrovascular Diseases" of the Fourth Conference on Cerebrovascular Diseases of the Chinese Medical Association and are confirmed by brain CT or magnetic resonance and other related imaging examinations with a course of disease of 2 weeks to 6 months. (2) Meet the diagnostic criteria for insomnia in the International Classification of Sleep Disorders - 3rd Edition (ISCD?3). (3) Insomnia degree in the Pittsburgh Sleep Quality Index (PSQI) score > 7 points. (4) Those who have no comprehension disorder and no cognitive dysfunction, and can fully understand the scale and cooperate with treatment. (5) Patients and their families should understand the purpose of the study and sign written informed consent.

Exclusion criteria

Exclusion criteria: (1) accompanied by failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, and unstable conditions. (2) deterioration of the condition, new cerebral infarction or secondary cerebral hemorrhage. (3) People with severe cognitive and communication disabilities. (4) There are treatment contraindications such as hearing AIDS in the ear and metal foreign bodies in the body. (5) Combined with decompensated respiratory insufficiency and severe sleep apnea syndrome. (6) Patients with a history of insomnia before ischemic stroke. (7) Taking strong tea, coffee and other food or drugs that affect sleep.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Indexs;

Secondary

MeasureTime frame
Self-Rating Anxiety Scale ;

Countries

China

Contacts

Public ContactJun Tian

Zhongnan Hospital of Wuhan University

tianjun@znhospital.cn+86 189 9554 0980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026